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ABSTRACT  
In oral absorption of a drug, the drug first dissolves and then is absorbed by diffusion through gastrointestinal membranes. The gastrointestinal 
environment is aqueous in nature and it is well-known that one-third of the drug population is water insoluble. Hence, there is a need for 
enhancement of the solubility and dissolution of such drugs. In this work, enhancement of the solubility and dissolution of the practically 
insoluble drug Rosuvastatin Calcium was achieved by formation of nanohybrids using microwave-induced diffusion (MIND), which ultimately 
leads to bioavailability enhancement. nanohybrids were formed by using natural carriers such as acacia,guar gum and PVP k-30 with the help of 
microwaves. Selection of carriers was based on their surfactant and wetting properties. Solubility studies were carried out to establish the 
solubility-enhancing property of the nanohybrids. To support solubility analysis results, dissolution studies (i.e. powder dissolution and in-vitro 
dissolution) were carried out. The nanohybrids were characterized by Fourier transform infrared spectroscopy, differential scanning 
calorimetry, X-ray diffraction studies, scanning electron microscopy and transmission electron microscopy. It was found that as the 
concentration of polymer in the composite increased the solubility and dissolution of rosuvastatin calcium were enhanced. The optimised ratio 
(drug : polymer) for all the composites was found to be 1:4. The novelty of this work is the green and cost-effective way of forming drug 
nanocomposites with the help of microwave, which can be scaled up to an industrial level. The method gives an immaculate means of 
solubilisation by generating drug dispersion at the micro and nanoscale level in natural biodegradable stabilising media. Hence, this study 
demonstrates the use of nanohybrids in solubility and dissolution enhancement. 
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INTRODUCTION 
The oral route is the major way of dosing both existing and 
new drugs. Most of the drugs which administrated by oral 
route are absorbed by passive diffusion through the gastro-
intestinal (GI) cellular membranes. The solubility and 
permeability are the most important tools for determining 
the oral bioavailability of a specific drugs within the GI tract, 
which have aqueous environment. According to US 
pharmacopoeia more than 40% of the drugs are poorly 
soluble or insoluble in aqueous environments. The 
enhancement oral bioavailability of poorly water-soluble 
drugs represent an actual challenge for pharmaceutical 
research, with the aims of improving drug therapeutic 
effectiveness as well as creating new market opportunities. 
The BCS class II drugs are water-insoluble (solubility equal 
or less than 100 µg of solute per 1 ml of solvent) but have 
high membrane permeability is only limited by dissolution. 
The energy-driven step is dissolution of crystalline solid in 
an process. In general, the kinetics of the process depends on 
solute, solvent chemical nature, microstructure and on the 
system conditions. It is possible to show that the dissolution 
rate of a crystalline drug in a given dissolution environment 
can be increased by forcing it to assume a microstructure by 
the theories of dissolution and non-electrolytes solubility 
characterized in nanoscale (short range) periodicity. The 
latest and most effective approaches to water-insoluble 
drugs solubilization are based on generating a drug 
dispersion (at molecular and/or nanoscale level) in a 
stabilizing media, preferably in solid-state form. Our main 
approach is that the enhancing effects of Microwave (MW) 
heating on mass transport might provide a green, effective 
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instrument for generating such dispersions [1]. Rosuvastatin 
Calcium have an class of drugs which is statins and it used for 
lowering blood cholesterol level. It has very good intestinal 
permeability and short half-life(Tmax,19h).However, the 
factors like low aqueous solubility(0.1mg/mL), crystalline 
nature and hepatic first pass metabolism responsible for low 
oral bioavailability (20%) of Rosuvastatin[2]. Due to the poor 
performance, drug have to administrated in higher doses 
which can causes liver abnormalities, rhabdomyolysis, 
arthralgia and kidney failure [3].To avoid such side effects, 
salt formation[4] and inclusion complexes with b-
cyclodextrin[5] has been tried. A snanocomposites is a 
combination of two or more different materials with 
different properties of each and that are fused, by an effort to 
blend the best properties of both. A composite consists of 
two materials of varying natures and combination of those 
shows improved in their properties greater than that of 
individual [6]. The melting or fusion technique is one of the 
simple and efficient technique in the preparation of 
nanohybrids or/and bionanocomposites for the solubility 
and dissolution enhancement. Particle size reduction 
provides more surface area for absorption and rapid 
dissolution[7].Microwave radiation consists of 
electromagnetic waves with frequencies between the 
infrared and radio waves, which is in the range of 0.3–300 
GHz. It passes through materials and oscillate their 
molecules, which generating heat.The ability of microwave to 
penetrate any substance, which produced the heatin a 
sample at any point at a given time [8-9].The first and unique 
attempt was proposed by Kerk et al in the direction of 
bioavailability enhancement[10].prevent re-crystallization of 
the drug. The cross-linked polyvinylpirrolidone 
(Crospovidone) is first chosen matrix which constrains the 
drug into stable molecular clusters and/or nanocrystals by 
its 3D network [11-13]. 
The other matrix like cyclodextrin, is a torus-shaped 
molecule that forms molecular complexes with the drug[14]. 
In the present work, we developed a nanohybrids of 
rosuvastatin calcium using natural carriers such as gum 
acacia, guar gum and synthetic polymer like pvp k-30.The 
rosuvastatin nanohybrids were evaluated for drug content, 
solubility and dissolution studies. Varying ratios of drug and 
carrier were formulated and evaluated. To deduce the 
possible effects of the carrier on the drug, their physical 
mixtures(PM) were also formulated and compared with 
nanohybrids and plain drug for solubility analysis . 
Optimized nanohybrids were followed by DSC, XRD, SEM and 
TEM studies for confirmation of formation of nanohybrids. 
Finally in-vivo studies were carried out to elucidate the anti-
hyperlipidemic potential of optimized nanohybrids with 
comparison to pure drug. 
 
 
MATERIALS AND METHOD  
 Materials 
 Rosuvastatin calcium was generous gift from Mylan lab, 
Nashik, Maharashtra (India). Gum acacia, guar gum and PVP 
K-30 were purchased from Modern science, Nashik, 
Maharashtra(India). All the materials were of analytical 
grade. The materials were used as received without any 
further purification.  
Selection of natural gum  
Gum acacia and guar gum , PVP K-30 were studied for 
swelling index, foaming index, viscosity method which 
described by Murali M. B GV et al. 
Swelling Index (SI)  
Swelling index of gums was determined by modified method 
reported. 1gm of acacia,pvp k-30 and gaur gum was 
accurately measured and transferred to 100 ml measuring 
cylinder. The initial volume which occupied by gum was 
noted. Made up the volume upto the 100ml with distilled 
water. The open end of cylinder was sealed with aluminum 
foil and kept aside for 24 hrs. After 24 hrs volume of swelled 
gum was noted. The swelling index of gum was calculated by 
the following formula. 
Foaming Index  
The foaming index of gum was calculated to check the 
surfactant properties of the gum. Accurately weighed 1 g of 
gum and transferred it in 250 ml measuring cylinder. 100 ml 
distilled water was added in measuring cylinder to make 
dispersion. Resultant dispersion was vigorously shaken for 2 
minutes. The foaming index of gum calculated by the 
following equation, 
Foaming index = Hf – Hi 
 Where, Hf = Height of solution of gum after shaking; Hi = 
Height of solution of gum before shaking.   
Viscosity 
 Viscosity of gums was calculated by dissolving one gram of 
each acacia, PVP K-30,gaur gum in 100 ml of water (1% w/v 
solution). The viscosity of the carrier dispersions of acacia 
and modified gum karaya were measured by Brookfield 
viscometer using spindle 00 at 200 rpm. 
Formulation of physical mixture [7, 15, 16, 18] 
 Physical mixture of drug with polymer acacia (AC), guar 
gum, PVP K-30 were prepared by simple blending of drug 
with polymer in the ratio 1:1 to 1:6 .The quantity of pure 
drug and respected polymers were mentioned in Table 1. 
The physical mixture prepared to check the solubility 
enhancing property of nanohybrids as compared with 
physical mixture. 
 
Table 1: Formulation of physical mixture 
Ratios 
(for physical mixture) 
Quantity (mg) 
Rosuvastatin Calcium 
(drug) 
Gum acacia Guar gum PVP K-30 
1:1 500 500 500 500 
1:2 500 1000 1000 1000 
1:3 500 1500 1500 1500 
1:4 500 2000 2000 2000 
1:5 500 2500 2500 2500 
1:6 500 3000 3000 3000 
The resultant physical mixtures of rosuvastatin calcium with carriers acacia gum, guar gum and pvp k-30 are denoted by AAp, 
AGp and APp, respectively. Data are means ± SD, n = 3. 
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Preparation of nanohybrid  
For each sample, a physical mixture of rosuvastatin calcium 
and individual carrier (acacia gum, guar gum, PVP K-30) was 
made by homogeneous mixing. The weight-to weight (w/w) 
ratio of drug to the carrier was taken from 1 to 6 keeping 
amount of mixture constant. To this mixture, 4 ml of water 
was added for each gram of the drug–carrier mixture to 
make homogeneous slurry (the water was added for 
hydration of the carrier). A fixed amount of the slurry (5 g) 
was placed in a glass beaker with a Teflon stirrer 
(transparent to microwaves) and treated with microwave 
irradiation for different times at power of 560 W . The 
temperature of the mixture at the end of treatment was 
recorded using an inbuilt temperature measurement probe. 
The samples were then ground in a glass mortar and sieved 
to achieve a particle size of 80–250 mm. The nanohybrid of 
drug with the carrier (acacia gum, guar gum, PVP K-30) was 
respectively designated as follows: RSVACCM (1–6), RSVGGM 
(1–6), and GPZPVPM (1–6).   
Evaluation of nanohybrids 
Drug content analysis  
To study the amount of drug incorporated in the Nanohybrid, 
rosuvastatin calcium was extracted from the nanohybrid by 
dissolving them in 25 ml methanol. The resulting solution 
was filtered through a 0.2-micron membrane filter. The 
rosuvastatin calcium content in the methanolic extracts was 
analysed spectrophotometrically by using UV-Visible 
spectrophotometer (UV 1601; Shimadzu, Tokyo, Japan) at a 
wavelength of 241 nm, against the methanol as blank 
Solubility study  
 The solubility of rosuvastatin calcium, RSVACCP, RSVGGP, 
RSVPVPP, RSVACCM, RSVGGM, RSVPVPM  was determined in 
pH 6.8 phosphate buffer. The solubility of drug, physical 
mixtures and nanohybrid was determined by taking an 
excess amount of drug (30 mg) and nanohybrid (equivalent 
to 30 mg of drug) and adding them to 10 ml of solvent (pH 
6.8 buffer), in Teflon-facing screw-capped vials. The samples 
were kept at equilibrium for a period of 48 h on an orbital 
shaking incubator (CIS-24; Remi Instruments, Mumbai, 
India) at 37 0.5°C and 50 rpm. The supernatant fraction 
collected from the vials was filtered through a 0.2- micron 
membrane filter and analysed by UV-Visible 
spectrophotometer (UV 1601; Shimadzu) at a wavelength of 
241 nm. Ratio optimisation (drug: carrier) was done on the 
basis of the best solubility results obtained.  
 Powder dissolution test  
The powder dissolution test was carried out on rosuvastatin 
calcium nanohybrid following the USP XXIV Apparatus 2 
(paddle) method in 900 ml of pH 6.8 phosphate buffer as 
dissolution media maintained at 37 0.5 0C at 50 rpm. Powder 
containing 5 mg (or equivalent to 5 mg of) rouvastatin 
calcium was added to dissolution media. At predetermined 
times (5, 10, 15, 30 and 45) 5-ml samples were collected 
periodically and replaced with fresh dissolution medium. 
After filtration through a 0.2-micron membrane filter 
samples were analysed spectrophotometrically at 241 nm. A 
cumulative correction was made for the removed samples 
while determining the total amount of drug dissolved. All 
experiments were run in triplicate. Dissolution profiles of 
rosuvastatin calcium nanohybrid were compared with that of 
the pure drug rosuvastatin calcium at the same experimental 
conditions. 
Fourier –transform infrared spectroscopy (FTIR)  
FTIR study of drug and optimized ratio of nanohybrid (APN 
1:4) was carried out. Nanohybrid were mixed with 
potassium bromide (KBr) of IR grade in a ratio of 1:100 and 
compressed using a pellet pressed at 15 tones pressure. 
Then pellets were scanned using an FTIR spectrophotometer 
(Shimadzu, 8400S). The FTIR spectra of optimized 
nanohybrids were compared with that of the pure drug to 
assess any change in the principal peaks of spectra of 
optimized nanohybrid. 
 Differential Scanning calorimetry (DSC)  
A DCS study of optimized nanocomposites ratio (APN 1:4) 
was employed to access what changes had actually made 
when nanohybrid were formulated and by what fact these 
enhances the solubility of drug. The DSC curves were 
obtained by Differential Scanning Calorimeter (Shimadzu, 
DSC 60, Japan) at the heating rate of 10°C/ min from 50 to 
200° in nitrogen atmosphere. 
X-ray diffraction studies (XRD) 
 XRD studies of drug rosuvastatin calcium and optimized 
nanohybrid (APN 1:4) were carried out to investigate the 
change in crystallinity when drug was mixed with polymer. 
XRD pattern were recorded using with Cu-kα radiation 
(D500, Siemens Diffractometer). The scanning angle ranged 
from 10° to 80° of 2θ. XRD Study was carried out to assess 
the changes in the crystalline made when the drug was 
mixed with carriers. 
Scanning electron microscopy (SEM)  
Scanning electron microscopy was used to examine external 
surface morphology. The morphologies and detailed particle 
structural characterizations of pure drug and nanohybrid 
(APN 1:4) were observed by scanning electron microscope 
(JEOL JSM-630 J, Scanning Electron Microscope). Nanohybrid 
that showed the best results in the solubility and dissolution 
studies were subjected to scanning electron microscopy 
(SEM) studies to confirm the changes made during the 
formation of nanohybrid. Samples were prepared by 
mounting powder onto a brass stub using graphite glue and 
coated with gold under vacuum before use. Images were 
recorded at the required magnification at an acceleration 
voltage of 10 KV using a scanning electron microscope. 
Transmission electron microscopy (TEM)  
The drug rosuvastatin calcium and optimized ratio of 
nanohybrid (APN 1:4) showing the best results in the 
solubility and dissolution studies was subjected to 
transmission electron microscopy (TEM) studies to confirm 
the formation of nanocrystals embedded in composites. The 
particle size and shape of pure drug crystal dispersed in 
polymer were analyzed with trmission electron microscopy. 
The morphology of the nanohybrid was obtained by 
transmission electron microscope (PHILIPS CM200, 
Transmission Electron Microscope). 
Preparation of sustained-release tablets 
The ratios of nanohybrids  that showed the best results in 
solubility and dissolution studies were selected for 
formulating the sustained-release tablets. The composition 
of tablets was as shown in Table 2. All the components of the 
tablets were sieved through a #60 sieve, weighed, mixed and 
compressed by direct compression into tablets using a 7-mm 
punch for RSVAPNM tablets on rotary tablet minipress . 
Evaluation of sustained-release tablet  
Pre-compression evaluation  
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Pre-compression evaluation included measurement of angle 
of repose, Carr’s index (compressibility) and Hausner’s ratio 
of optimised BNC and various formulation mixtures, 
following the procedures given in USP 30 (2007).  
Post-compression evaluation  
Post-compression evaluation included measurement of 
weight variation, hardness, friability, drug content of 
prepared formulations, following the procedures given in 
USP 30 (2007). 
Assay of the total drug content  
Drug content analysis was performed to study the amount of 
drug incorporated in tablets. Rosuvastatin Calcium from 
powdered tablets was extracted by dissolving the tablets in 
25 ml methanol. The resulting solution was filtered by using 
a 0.2- micron membrane filter. Rosuvastatin Calcium  content 
in the methanolic extract was analysed 
spectrophotometrically at 241 nm against the methanol as 
blank. 
 In-Vitro Dissolution Test  
The dissolution test was carried out in USP apparatus type II 
(paddle) with Phosphate buffer pH 6.8 as the dissolution 
medium of 500ml quantity at 50 rmp. The samples were 
drawn at 0,1,2,3,4 and 24 hours.fresh volume of the medium 
was replaced with the withdrawn volume to maintain the 
sink conditions. Samples withdrawn were analyzed by using 
UV-Visible spectrophotometer at 241 nm for assessing the 
percentage of drug released. 
Dissolution apparatus:  
USP apparatus type ll(paddle) 
 Dissolution medium: Phosphate Buffer pH6.8 
Volume: 500 ml  
Temperature: 37+ 2c  
Rpm: 50  
Sampling intervals (min) : 1,2 ,3,4,5 hours 
Specification: NLT80%(Q) of the labelled amounts of 
rosuvastatin 
 Stability study 
Optimised formulation was subjected to stability studies 
according to ICH guidelines. Various variables, such as drug 
content, disintegration time and in-vitro drug release, were 
measured before and after 30, 60 and 90 days of storage. 
There was no significant change in the above-mentioned 
variables following the elevated temperature and humidity 
conditions imposed during the stability study. Thus, it can be 
concluded that the prepared formulation is stable and not 
much affected by elevated humidity and temperature. 
RESULTS AND DISCUSSION 
Preliminary Investigation of Rosuvastatin Calcium 
Saturation solubility of pure Rosuvastatin calcium in water, 
methanol and phosphate buffer pH 6.8 were determined. The 
results suggest that Atorvastatin calcium has very less 
solubility (0.028 mg/ ml) in water. The melting point was 
observed 158-160°C. 
Selection of Natural Gum 
Swelling characteristics and viscosity of the gums are 
presented in Table19. From this data, it can be concluded 
that the swelling characteristics and viscosity of acacia gum, 
guar gum,PVP k-30 were low. The High viscosity and 
toughness of the carrier may affect its dissolution 
enhancement property. According to past results it known 
that less swelling and low solution viscosity, they are more 
prone to dissolution enhancement. They are less prone to the 
formation of the tough matrix which will assist rapid 
liberation of the nanocrystals from the nanohybrid. The 
foaming index clearly indicates the greater foaming ability of 
PVP K-30 from other carriers. Hence, PVP K-30 enhances the 
solubility more efficiently than the other carriers. 
 
Table 2:Physical characterization of polymer 
Material % Swelling Viscosity (cp) Foaming Index 
Acacia 65.66± 1.20 2.22±0.13 7 ±0.45 
Guar gum 72.12± 1.02 2.21±0.11 5±0.60 
PVP K-30  75.13± 1.03  2.20± 0.14 8±0.40 
Data are means ± SD, n = 3. 
 
Evaluation of nanohybrid 
In-vitro Solubility studies 
Solubility studies were performed to find out the solubility 
enhancing properties of nanohybrid. Solubility studies 
provided the basis for selection of the best ratio that was to 
be forwarded for formulation. Pure drug Rosuvastatin 
calcium and physical mixtures of Rosuvastatin with 
individual carriers in varying ratios, as well as nanohybrid  of 
Rosuvastatin with individual carrier in varying ratios were 
analyzed for solubility determination. The solubility of pure 
drug was found to be 0.028 mg/ml in water and 0.112 
mg/ml in phosphate buffer pH 6.8. The results of solubility 
studies of a various ratios of physical mixture and 
nanohybrid are presented in Table 20 . Solubility studies 
reveals that physical mixtures improves the solubility of RSV 
significantly compared with pure drug .This may be due to 
the surfactant and wetting property of acacia gum, guar 
gum,PVP K-30. In case of nanohybrid solubility data indicates 
a tremendous rise in solubility compared with pure drug; 
this may be due to reduction of crystal size of the drug to a 
nanocrystalline form. This aspect is to be investigated by 
performing SEM and X-ray diffraction analyses. 
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Table 3  : Solubility of Physical mixture and Nanohybrid of Rosuvastatin Calcium 
Drug polymer 
Ratio 
AAP 
mg/ml 
AGp 
mg/ml 
APp 
mg/ml 
AAN 
mg/ml 
AGN 
mg/ml 
APN 
mg/ml 
1:1 0.204±0.01 0.347±0.07 0.501±0.04 0.255±0.02 0.829±0.03 1.046±0.05 
1:2 0.650±0.06 0.526±0.09 0.680±0.09 1.424±0.04 1.066±0.08 1.392±0.08 
1:3 0.695±0.07 0.617±0.06 0.614±0.04 1.547±0.04 1.164±0.12 1.538±0.03 
1:4 0.501±0.04 0.695±0.05 0.883±0.08 1.627±0.08 1.200±0.02 1.639±0.09 
1:5 0.739±0.06 0.549±0.19 0.628±0.10 1.402±0.05 0.661±0.10 0.740±0.03 
1:6 0.481±0.14 0.448±0.11 0.402±0.01 0.897±0.06 0.436±0.06 0.515±0.06 
Data are means ± SD, n = 3. 
 
Solubility studies of physical mixtures and nanohybrid 
clearly indicated that as the ratio of     drug to carrier 
increases solubility up to specified ratio. It was also found 
that the high solubility was shown by nanohybrid 
formulation and nanohybrid prepared by using PVP K-30 
(APN) showing best solubility result at 1:4 ratio was 
considered optimal. The solubility of APN was found to be 
1.639 mg/ml. AAN (1:5), AKN (1:4), APN(1:4) are the best 
ratios from different drug: polymers nanohybrids 
formulations, which were showing high solubility, hence 
those were subjected to invitro drug release study with pure 
drug and drug content analysis. 
In-vitro Drug release 
A powder dissolution test was performed because the 
solubility studies are not always a predictable parameter to 
determining the solubility enhancing properties of any 
material.  
 
Fig 1 . Dissolution Profile of Pure Drug AAn, AGn, APn 
The dissolution studies of Rosuvastatin and Rosuvastatin  
(NBs) give more specific information about the solubility 
and dissolution of drug. The dissolution profile of pure drug 
and NBs is presented in fig. . From the dissolution profiles of 
the NBs, there was evidently a remarkable improvement of 
the dissolution rates in all NBs compared with the pure 
Rosuvastatin. All Of the NBs, the best result was shown by 
APN which show the drug released 84.72% in comparison to 
pure Rosuvastatin which released 48.47%. From the 
solubilition and dissolution studies the APN was selected for 
formulating the dosage form. 
Drug content analysis  
Uniform dispersion of drug in the nanohybrid can be 
determined by drug content analysis. It was found that 85-
92% drug was incorporated in the nanohybrod. APN (1:4) 
showing uniform dispersion of drug in the nanohybrid. Drug 
content analyses are presented in Table   
Table 4 : Drug Content analysis of nanohybrids 
Nanohybrids AAN AGN APN 
Drug 
Incorporated 
89.42±0.5
4% 
85.82±0.50
% 
91.42±0.66
% 
Solid state studies of optimized nanohybrids 
The optimized ratio APN 1:4 further characterized by 
following parameters. 
Fourier –transform infrared spectroscopy (FTIR) 
 FT-IR of A) Pure Drug B) Optimized Nanohybrids  
 
  
 
Fig  2 : FT-IR of A) Pure drug B) Optimized Nanohybrids 
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Differential Scanning calorimetry (DSC)  
DSC was performed to detect the interaction between 
Rosuvastatin calcium and polymer. The DSC thermogram of 
pure drug shows a sharp endothermic peak corresponding to 
the melting point of crystalline drug was found to at 
159.03°C. DSC of optimized nanohybrids APN 1:4 shows 
slight variation in endothermic peak as that of pure drug and 
intensity of peak is reduced this may be due to the decrease 
in the crystalline size of the drug. The DSC thermogram of 
APN at 143.050C had shown a broad endothermic peak. The 
peak broadening indicated that most of the drug is 
embedded in NBs in the nanocrystalline form. Little shift in 
melting point was observed due to reduction of drug to the 
nanocrystalline form. This phenomenon is responsible for 
the solubility enhancement as the crystallinity has been 
reduced to the nanocrystalline form solubility get enhanced. 
DSC thermogram of pure drug and nanohybrids are shown in 
fig. 
 
 
 
Fig 3  :DSC Thermo gram of A) Rosuvastatin Calcium B) Optimized nanohybrid 
 
X -Ray Diffraction Studies (XRD) 
The X-ray diffraction studies (XRD) of Rosuvastatin calcium 
(ATR) and optimized nanohybrid APN 1:4 are shown in 
figure. The pure (ATR) exhibit intense crystalline peak 
between 10° and 50°, characteristic diffraction peaks at 
10.44°, 11.90 °, 17.04°, 19.33°, 23.40°, 24.82°, 28.83o , 
30.43o and 37.33 ° were observed with intense peak at 
21.58° indicating the crystalline nature of RSV. On the other 
hand APN it’s observed that the peak intensity is reduced 
indicating reduction in crystallinity. This phenomenon is 
also responsible for enhancement of solubility. XRD pattern 
of pure drug and nanohybrids were showed in fig
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Fig 4  . : XRD Pattern of (A) Rosuvastatin Calcium and (B) optimized nanohybrids 
Scanning electron microscopy (SEM)  
SEM studies are usually done to study the surface 
morphology of drug particles. Rosuvastatin calcium and 
optimized nanohybrid APN 1:4 were characterized by SEM. 
From the fig19, it is concluded that pure Rosuvastatin 
calcium drug showed needle and plate shaped with smooth 
surface while in case of APN it was observed that they were 
irregular shape and size. Figure clearly shown that crystal 
shaped of Rosuvastatin calcium completely changes in 
nanohybrid which showing embedded Rosuvastatin crystal 
in the matrix of polymer (PVP K-30). 
 
Fig5 : SEM images of (A) Rosuvastatin Calcium (B) optimized nanohybrids 
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Transmission electron microscopy (TEM)  
The TEM of pure drug and optimized nanohybrid APN 1:4 
are shown in the following fig20. . The TEM image of drug 
was observed first at 200 nm. In that image the drug is 
showing dark colour particles and pure drug image of TEM at 
100 nm had shown the large free particles can be observed 
in somewhat cubic and rod shaped structure. After 
preparation of nanohybrid (APN) those were shown drug 
and polymer is mostly mixed looking flowery and most of the 
drug has transformed with the polymer. The polymer 
background which has more brightens and therefore drug is 
looking on the surface of polymer at 50 nm. When this 
preparation is observed at 20 nm the polymer is in 
background and the rod shaped structure of drug has 
converted into somewhat square shaped which shows that 
there is reduction of particle size of drug when it was treated 
with MIND method and all drug and polymer are finely 
embedded in each other. 
 
 
Fig 6. : TEM images of (A) Rosuvastatin calcium (B) optimized nanohybrids 
 
Evaluation of sustained-release tablets  
Pre-compression evaluation   
All the formulation mixtures were subjected to measurement 
of angle of repose, Carr’s index and Hausner’s ratio. The 
results are shown in Table . From the angle of repose, Carr’s 
index and Hausner’s ratio data, it can be clearly concluded 
that RSVAPN and its mixture with different formulation 
components have excellent flow properties and fairto-good 
compressibility, which allows these formulation mixtures to 
be directly compressed into tablets and good flow of the 
mixture from the hopper with good content uniformity in the 
final tablets.  
Post-compression evaluation 
 Prepared formulations were subjected to various 
compendial tests for post-compression evaluations such as 
hardness, friability, content uniformity of prepared tablets, 
DT. The results are shown in Table . All the parameters were 
within the limits given in the USP 30 (2007). 
 
Table5 :  Pre- compression evaluation of RSVAPM 
 
Formulation 
Bulk Density 
G/CC 
Tapped 
Density 
G/CC 
Hausner 
Ratio 
Compressibility 
Index % 
Angle of 
Repose 
F1 0.51±0.05 0.56±0.02 1.15±0.05  2.72±0.02  26.21±0.01 
F2 0.50±0.03 0.58±0.03 1.17±0.02  12.24±0.03 20.48±0.04 
         F3 0.53±0.01 0.57±0.02 1.16±0.03  13.11±0.03  24.38±0.01 
F4 0.55±0.04 0.59±0.01 1.18±0.01 13.85±0.06 27.40±0.05 
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Table 6 : Physical evaluation of matrix tablets 
Formula 
Code 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
Weight 
variation 
(mg) 
Friabiity 
(%) 
Assay *%) 
           F1 4.7±0.12 4.28±0.13   316.3±0.15  0.18±0.12   90.15±0.12 
           F2 4.5±0.13 4.22±0.12   313.7±0.12  0.14±0.12   99.53±0.14 
       F3        4.2±0.11 4.10±0.13   313.5±0.13  0.21±0.14   99.15±0.13 
       F4 5.1±0.14 4.42±0.15   316.5±0.13  0.22±0.16 100.24±0.12 
 
In-Vitro Drug Release Studies   
The in-vitro dissolution studies were performed using the 
USP-I1 (Paddle) dissolution apparatus at 50 rpm. The 
dissolution medium consisted of 900ml of phosphate buffer 
pH 6.8, maintained at 37±0.5 C. An aliquot (5ml) was 
withdrawn at specific time intervals and drug content was 
determined by UV-visible spectrometer at 241 nm. 
 
Table  7: in-vitro drug release data of Rosuvastatin Calcium from formulations F1 to F4  and comparative with 
Marketed product 
Time in Hrs 0 1   4   8 12 16 20 
% Drug release inF1 0 11.40±1.1 2 24.50±1.2 40.10±2.2 54.05±1.4 60.05±2.3 64.05±1.4 
% Drug release in F2       0 10.70±0.2 24.62±1.3   44.31±2.3 58.31±2.2 54.1±1.2 69.31±2.2 
 %Drug release in F3        0 9.63±0.3 26.81±1.6 46.94±1.9 59.35±2.4 71.1±2.1 79.35±2.4 
%Drug release in F4            0 15.6±0.4 35.6±1.1 53.5±0.2 68.09±2.6 73.0±1.2 95.09±2.6 
% Drug release in marketed 
product 
0 13.3  33.8  51.5 68.02 `73.0 80.02 
 
 
Fig.7  : In-vitro drug release profiles of Rosuvastatin Calcium from F1 to F4 
 
CONCLUSION 
This study successfully demonstrated the use acacia gum, 
guar gum and pvp k-30 as carriers for the formation of 
microwave-generated nanohybrids in the solubility and 
dissolution enhancement of rosuvastatin calcium. Solubility 
and dissolution studies confirmed the use of these materials 
for solubility enhancement. This demonstrates the 
possibility of using BNCs as drug delivery systems, 
particularly using the MIND technique. The RSVPVPM 
nanohybrids showed the best results regarding solubility 
and dissolution enhancement. From the FTIR, DSC, XRD, SEM 
and TEM characterization it can be concluded that 
rosuvastatin had been converted to nanocrystals in the 
composites and this was responsible for the solubility 
enhancement. Characterisation confirmed that there was no 
interaction between the drug and polymers. In-vitro  
assessment of optimised formulations further confirmed the 
use of nanohybrids for enhancing solubility and dissolution 
by use of natural carriers. The stability studies showed that 
the nanohybrids-containing formulations were stable. Here 
we have demonstrated that it is indeed possible to prepare 
nanohybrids using rosuvastatin as a model drug. Key feature 
of this study include the uniform distribution of drug in 
carrier in a nanocrystalline form, which is sufficiently stable 
and easy to prepare. Finally from these studies overall we 
can conclude that microwave-generated nanohybrids can be 
successfully used for the enhancement of solubility, 
dissolution and bioavailability. 
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